Toxicity, pharmacokinetics, and in vivo efficacy of biotinylated chitosan surface-modified PLGA nanoparticles for tumor therapy

Abstract

Based on our previous work on the PLGA nanoparticles modified with biotinylated chitosan (Bio-CS-PLGA NPs), we further studied the stability, toxicity, pharmacokinetics, and in vivo efficacy. The safety of NPs was studied through single-dose toxicity test in mice, and the result showed that NPs were well tolerated at the dose of 300 mg/kg. Compared with the free EPB group, the NPs group exhibited higher plasma drug concentration, longer half-life time. EPB-loaded NPs significantly inhibited the tumor growth compared to free EPB. All results suggested that Bio-CS-PLGA NPs were stable, safe, and showed a promising potential on targeted drug delivery.

Keywords:

• Biotin
• chitosan
• pharmacokinetics
• PLGA nanoparticle
• toxicity
• tumor

Disclosure statement

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of this article.

Funding information

This research was supported by the grants from the National Natural Sciences Foundation (No.U1304819, No.81401519), the Key Technologies R&D Program of Henan Province (No. 122102210148), and National Training Programs of Innovation and Entrepreneurship for Undergraduates (No. 201410472030).